Dofetilide Initiation Protocol
Dofetilide must be initiated in a hospital setting with continuous ECG monitoring for a minimum of 3 days, with dosing strictly based on creatinine clearance and QTc monitoring to minimize the risk of torsades de pointes. 1
Pre-Initiation Requirements
Absolute Contraindications - Do Not Initiate If:
- QTc >440 ms (or >500 ms with ventricular conduction abnormalities) 2, 1
- Creatinine clearance <20 mL/min 2, 1
- Concomitant use of: cimetidine, verapamil, hydrochlorothiazide (alone or in combinations), trimethoprim/sulfamethoxazole, prochlorperazine, megestrol, ketoconazole, dolutegravir, or itraconazole 2, 1
- History of torsades de pointes 2
Mandatory Baseline Testing
Before administering the first dose 3, 1:
- 12-lead ECG with QTc calculation (average 5-10 beats)
- Serum creatinine for creatinine clearance calculation
- Serum potassium and magnesium - must be within normal range (generally maintained >3.6-4.0 mEq/L in trials) 4, 1
- Anticoagulation status - patients with AF should be anticoagulated per usual practice before cardioversion 1
Dosing Algorithm Based on Renal Function
Calculate creatinine clearance using the Cockcroft-Gault equation 1:
Males: CrCl = (140 - age) × weight (kg) / (72 × serum creatinine mg/dL)
Females: CrCl = (140 - age) × weight (kg) × 0.85 / (72 × serum creatinine mg/dL)
Starting Dose 2, 1:
| Creatinine Clearance | Dofetilide Dose |
|---|---|
| >60 mL/min | 500 mcg twice daily |
| 40-60 mL/min | 250 mcg twice daily |
| 20-<40 mL/min | 125 mcg twice daily |
| <20 mL/min | Contraindicated |
In-Hospital Monitoring Protocol
QTc Monitoring Schedule 2, 1:
- 2-3 hours after EACH dose (doses 1-5), measure QTc
- Continuous ECG monitoring for minimum 3 days
- Minimum 12 hours monitoring after electrical or pharmacological cardioversion to sinus rhythm, whichever is greater
Dose Adjustment Criteria 1:
Reduce dose by 50% if:
- QTc increases by >15% from baseline, OR
- QTc exceeds 500 ms (550 ms with ventricular conduction abnormalities)
Dose reduction table:
| Current Dose | Adjusted Dose |
|---|---|
| 500 mcg BID | 250 mcg BID |
| 250 mcg BID | 125 mcg BID |
| 125 mcg BID | 125 mcg once daily |
Discontinue dofetilide immediately if:
- After the second dose, QTc >500 ms (550 ms with ventricular conduction abnormalities) 1
Critical Monitoring Points
During Initiation 4:
- The majority of torsades de pointes occurs within the first 3 days (10/11 events in supraventricular arrhythmia studies occurred in this window)
- Risk of torsades de pointes: 0.8% overall in supraventricular arrhythmia population, but 3.1% before renal-based dosing protocols vs 0.4% after implementation 4
- Two patients receiving 500 mcg BID in congenital heart disease studies experienced torsades de pointes 4
Ongoing Monitoring (Post-Discharge) 3:
Every 3-6 months (more frequently if taking other QT-prolonging drugs or changing renal function):
- 12-lead ECG with QTc calculation
- Serum potassium and magnesium
- Serum creatinine for creatinine clearance estimation
Discontinue if:
- QTc exceeds 500 ms (550 ms with ventricular conduction abnormalities) 1
- Renal function deteriorates - readjust dose per algorithm 1
Special Considerations
Drug Interactions 1:
- Avoid all QT-prolonging drugs 2
- If anti-ulcer therapy needed, use omeprazole, ranitidine, or antacids (aluminum/magnesium hydroxide) - NOT cimetidine
- Assess all over-the-counter, prescription, and herbal preparations before initiation
Electrolyte Management 1:
- Correct hypokalemia and hypomagnesemia before initiating dofetilide
- Patients should report symptoms of electrolyte imbalance (excessive diarrhea, vomiting, sweating, loss of appetite/thirst) immediately
Cardioversion 1:
- If no conversion to sinus rhythm within 24 hours, consider electrical cardioversion
- Continue ECG monitoring for 12 hours post-cardioversion OR minimum 3 days after dofetilide initiation, whichever is greater
Common Pitfalls to Avoid
- Never initiate dofetilide outpatient - FDA mandates hospital initiation 5, 1
- Do not double dose if missed - take next dose at usual time 1
- Do not discharge within 12 hours of cardioversion even if 3-day monitoring complete 1
- Ensure adequate dofetilide supply at discharge to prevent interruption until prescription filled 1
- Patients with heart failure, reduced LVEF, increased LV end-diastolic diameter, increased LA diameter, or reduced RV function are at higher risk for excessive QTc prolongation requiring discontinuation 6
Role in Clinical Practice
Dofetilide is a reasonable alternative to amiodarone as first-line therapy in adults with ventricular dysfunction, or as second-line therapy in those without structural heart disease 4. Unlike amiodarone and dronedarone, dofetilide has not been associated with increased mortality in high-risk patients with recent MI or heart failure 4. The strict FDA-mandated initiation protocol, while cumbersome, has reduced torsades de pointes risk from 3.1% to 0.4% 4.